Monoclonal Antibody Cocktail Protects Hamsters From Lethal Marburg Virus Infection

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Marburg virus (MARV) causes severe Marburg hemorrhagic fever (MHF) with high mortality.
• No approved therapeutics exist for MHF, necessitating novel treatment strategies.
• Monoclonal antibodies (mAbs) are being explored as potential antiviral therapies.

Purpose of the Study:

• To enhance the therapeutic efficacy of the neutralizing mAb M4 against MARV.
• To evaluate the combination of neutralizing mAb M4 with blocking, non-neutralizing mAbs (126-15 and 127-8).
• To identify an optimal mAb cocktail for treating MARV infection.

Main Methods:

• Utilized a MARV hamster model to assess therapeutic interventions.
• Administered single-dose treatments with mAb M4 alone or in combination with mAbs 126-15 and/or 127-8.
• Evaluated treatment efficacy based on animal survival rates following lethal MARV challenge.
• Compared outcomes for early and delayed treatment administration.

Main Results:

• Single-dose treatment with M4 or any mAb combination showed similar protection when administered early post-infection.
• A cocktail of all three mAbs (M4, 126-15, and 127-8) provided the best protection in delayed treatment scenarios.
• Survival rates with the three-mAb cocktail ranged from 67% to 100% depending on treatment timing.
• This combination therapy demonstrated significant therapeutic potential for MARV infection.

Conclusions:

• A combination of neutralizing and non-neutralizing mAbs offers improved therapeutic efficacy against MARV.
• The identified mAb cocktail represents a promising therapeutic option for Marburg hemorrhagic fever.
• Further research into mAb cocktails could lead to effective treatments for filoviral hemorrhagic fevers.